Alex Y. Chang

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Nick Thatcher, Alex Y. Chang, Purvish M. Parikh et al. · The Lancet · 2005 · 2.1K citations

Medicine, Oncology, Palliative Oncology +9

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Fred R. Hirsch, Marileila Varella‐Garcia, Paul A. Bunn et al. · Journal of Clinical Oncology · 2006 · 703 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Wan‐Teck Lim, Boon Cher Goh, Edwin P. Hui et al. · Journal of Clinical Oncology · 2018 · 466 citations · Full text

Medicine, Oncology, Pharmacology +17

Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia

Alvin Wei Tian Ng, Song Ling Poon, Mi Ni Huang et al. · Science Translational Medicine · 2017 · 378 citations

Medicine, Oncology, Toxicology +10

Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Anthony T.�C. Chan, Mow-Ming Hsu, Boon Cher Goh et al. · Journal of Clinical Oncology · 2005 · 292 citations · Full text

Medicine, Oncology, Pharmacology +17